Home Your basket
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Study on the modeling of ...
   Price 10.50 €
• Botulinum toxin and rejuv...
   Price 10.50 €
• Vocal effectiveness in sp...
   Price 10.50 €
• One-stage surgery of midd...
   Price 8.50 €
• Interest of hypnotherapy ...
   Price 10.50 €
• The clinical significance...
   Price 5.50 €
• Stingy speakers....
   Price 5.50 €
• Blepharoplasty and upper ...
   Price 10.50 €
• Parapharyngeal tumours: M...
   Price 10.50 €
• MIF in Head and Neck canc...
   Price 10.50 €
• Polymorphisms of the huma...
   Price 10.50 €
• Clinical signs and correl...
   Price 10.50 €
• Central auditory processi...
   Price 10.50 €
• Evaluation of a dysphonic...
   Price 10.50 €
• The Bell Labs contributio...
   Price 12.50 €
• Acoustic neuroma surgery....
   Price 10.50 €
• Bilateral and recurrent f...
   Price 5.50 €
• Assessment of migraine re...
   Price 8.50 €
• Esthesioneuroblastoma....
   Price 5.50 €
• Correlation between the r...
   Price 12.50 €
• Determination of oesophag...
   Price 10.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• F0 characteristics in Par...
   Price 12.00 €
• Benign positional vertigo...
   Price 8.50 €
• Modern lipostructure: The...
   Price 10.50 €
• How to take a mastoid and...
   Price 8.50 €
• Bilateral abductor vocal ...
   Price 14.00 €
• Does indermil glue improv...
   Price 5.50 €
• Transsexuality: Speech th...
   Price 10.50 €
• Free novascularized bone ...
   Price 15.00 €
• Prosodic analysis of spee...
   Price 10.50 €
• Clinical implementation o...
   Price 5.50 €
• Changing patterns of bucc...
   Price 10.50 €
• Vocalab: A new software f...
   Price 8.50 €
• Sinonasal malignant melan...
   Price 5.50 €
• Recurrences of pleomorphi...
   Price 10.50 €

Total Order 347.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 2 - 2014 o

PHONIATRICS

F0 characteristics in Parkinsonian speech: Contrast between the effect of hypodopaminergy due to Parkinson’s disease and that of the therapeutic delivery of L-Dopa


Authors : Ghio A, Robert D, Grigoli C, Mas M, Delooze C, Mercier C, Viallet F. (Aix-en-Provence)

Ref. : Rev Laryngol Otol Rhinol. 2014;135,2:63-70.

Article published in french
Downloadable PDF document french



Summary : Voice and speech impairments are frequent in Parkinson’s disease, particularly when the disease is at an advanced stage. These impairments affect spoken communication and may become a serious disability for someone with Parkinson’s disease. Many studies based on auditory-perceptual or acoustic methods have been carried out to characterize dysarthria. The heterogeneity of evaluation methods and experimental bias however make results difficult to understand. For instance, in terms of phonatory impairments and with regard to F0, results are contradictory : PD speech may be characterized by either higher F0 or lower F0 compared to control subjects, or there may be no difference at all between the two population. In this study, we aim to provide a conceptual and methodological framework which allows for interpreting the results obtained from 44 speakers (29 PD and 15 control subjects) in relation to physiological (gender, age, PD subjects’ pharmacologic state) and linguistic (speech production tasks) constraints. For the present corpus, we did not observe any F0 mean difference between the two groups. Our results however reveal a significant increase in F0 mean in PD subjects under L-dopa. We assume a double and opposite effect on F0 mean during drug withdrawal : low sub-glottal pressure, due to PD, results in a decrease in F0, while laryngeal rigidity leads to an increase in F0. These two effects thus mutually annihilate. Under L-Dopa, however, the drug effect increases sub-glottal pressure, which combined with an increase in F0 due to rigidity, leads to a global increase in F0.

Price : 12.00 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE